MAPT and amyloidosis: Thus, tau and neurodegeneration are discordant in the majority of NIA-AA preclinical AD stage 2/3 individuals at age 65 (86%) and in half at age 80 (51%) (Fig 3).30,31 A model of AD pathogenesis proposes that amyloidosis promotes increased local tau deposition and its spread, which in turn is responsible for neurodegeneration.